HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced...
Hence then, the article about akeso announces first patient enrolled in the phase iii trial ak112 312 harmoni gi6 of ivonescimab for first line treatment of advanced metastatic colorectal cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer )
Also on site :
- Ukraine-Russia war latest: Moscow warns UK ‘playing with fire’ over plans to help Kyiv produce missiles
- Don’t Sleep on These 11 Trader Joe’s September Gems Before They’re Gone for the Season
- Iran-US war latest: Tehran drafting list of conditions to open Hormuz as Trump sends new warship to Middle East